Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

Trial Profile

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASCENT; ASCENT COPD
  • Sponsors Actavis; AstraZeneca; Forest Laboratories
  • Most Recent Events

    • 18 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2017 Top-line results presented in the Circassia media release.
    • 04 Dec 2017 Primary endpoint (Rate of moderate or severe COPD exacerbations per patient per year during the first year of treatment) has been met, according to a Circassia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top